| Trial Name: |
HIV, Prevention of Fat Loss
|
| Intro: |
The HIV Metabolic Research Center is conducting the HIV Lipoatrophy Study to understand how HIV infected adults can avoid the disfigurement of fat loss. |
| Condition: |
|
| Description: |
The HIV Metabolic Research Center is conducting the HIV Lipoatrophy Study to understand how HIV infected adults can avoid the disfigurement of fat loss. This research study is investigating whether adding a nutritional supplement (Nucleomaxx) and/or substituting Viread for other drugs in an anti-HIV regimen can reverse fat loss. There are two arms to this study: in the first arm participants must be diagnosed with HIV lipoatrophy, receiving a stable AZT (Retrovir) containing regimen and the virus must be under good control; in the second arm participants are about to start their first ARV regimen (treatment naïve). That regimen must contain AZT as one part of the drug cocktail. |
| Criteria: |
Participants must be at least 18 years. Potential participants in either arm may be excluded for any bleeding disorders, diabetes requiring medication, kidney problems, current use of steroids or growth hormones, and/or are pregnant or breastfeeding. |
| Contact: |
For information or to register for screening in this trial please call HealthMatch at (216) 844-5000, or complete and submit the form below. |
Participant Confidentiality:
All information regarding participation in Clinical Trials is treated with the
utmost confidentiality. University Hospitals Case Medical Center and the
Division of Clinical Research recognize and respect the confidentiality of this
information. Access to information related to clinical trials and their
participants is restricted to authorized clinical trials personnel only.
Back